Travere Therapeutics Inc. (NASDAQ: TVTX) presented new data from its Phase 3 DUPLEX Study showing that patients with focal segmental ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE